Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Invested Capital (2019 - 2025)

Arcutis Biotherapeutics has reported Invested Capital over the past 7 years, most recently at $298.4 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 12.73% year-over-year to $298.4 million; the TTM value through Dec 2025 reached $298.4 million, up 12.73%, while the annual FY2025 figure was $298.4 million, 12.73% up from the prior year.
  • Invested Capital for Q4 2025 was $298.4 million at Arcutis Biotherapeutics, up from $266.6 million in the prior quarter.
  • Over five years, Invested Capital peaked at $467.5 million in Q3 2022 and troughed at $247.0 million in Q2 2025.
  • A 5-year average of $336.6 million and a median of $332.5 million in 2022 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: surged 109.74% in 2021 and later crashed 47.06% in 2023.
  • Year by year, Invested Capital stood at $370.0 million in 2021, then grew by 10.09% to $407.3 million in 2022, then fell by 28.69% to $290.5 million in 2023, then fell by 8.86% to $264.7 million in 2024, then increased by 12.73% to $298.4 million in 2025.
  • Business Quant data shows Invested Capital for ARQT at $298.4 million in Q4 2025, $266.6 million in Q3 2025, and $247.0 million in Q2 2025.